Presentation to Annual General Meeting
Released
Released
Announcement PDF
David Stamler, MD
CEO
AGM
22 November 2024
Forward Looking Statements
This presentation may contain some statements that
may be considered “Forward-Looking Statements”,
within the meaning of the US Securities Laws. Thus,
any forward-looking statement relating to financial
projections or other statements relating to the
Company’s plans, objectives, expectations or intentions
involve risks and uncertainties that may cause actual
results to differ materially. For a discussion of such
risks and uncertainties as they relate to us, please refer
to our 2023 Form 20-F, filed with US Securities and
Exchange Commission, in particular Item 3, Section D,
titled “Risk Factors.’’
2
Targeting Iron-Related Neurodegenerative Diseases
• Iron: central to pathology of many neurodegenerative
diseases
Friedreich
Ataxia
• Parkinsonian disorders include
• Parkinson’s disease (PD)
• Rare diseases with similar motor symptoms
•
Multiple System Atrophy (MSA)
•
Dementia with Lewy Bodies (DLB)
• Similar underlying pathology
Multiple
System
Atrophy
• Friedreich’s Ataxia
Parkinson’s
Disease
• Rare disease with uncoordinated movements
• Genetic disorder that appears in childhood
Parkinsonian
Disorders
Dementia
with Lewy
Bodies
3
Promising Portfolio in Neurodegenerative Diseases
ASSET
PHASE
DISCOVERY
PRECLINICAL
NATURAL
HISTORY
PARTNER
PROGRAM
INDICATION
ATH434-201
Multiple System Atrophy
Early Stage
Enrollment Complete
ATH434-202
Multiple System Atrophy
Advanced
Enrollment Complete
ATH434
Parkinson’s Disease
bioMUSE
Multiple System Atrophy
Natural History Study
ATH434
Friedreich’s Ataxia
Drug
Discovery
Neurodegenerative
Diseases
PHASE 1
PHASE 2
PARTNER /
COLLABORATOR
4
Significant Commercial Opportunity in Treating
Multiple System Atrophy
Substantial Unmet Need
Strong Intent to Prescribe
Severely debilitating illnesses
with no current treatments are
ripe for new entrants targeting
underlying pathology of the
disease.
Motivated by efficacy of treating
the underlying disease and not
just the symptoms, clinicians
intend to offer ATH434 to most
of their patients with MSA.
up to
$US1.1 Billion
Potential U.S.
annual peak sales
for ATH434 in MSA
Unique MOA
Inhibition of protein aggregation
is a novel mechanism of action
that may prove to impact more
than motor symptoms.
Source: Survey of U.S. neurologists, updated 2023
Ease of Use
Twice daily oral administration of
ATH434 preferred by physicians
5
Alpha-Synuclein and Iron in Health
α-Synuclein protein
• Critical for normal function of neurons
• Enables nerves to communicate with
each other via neurotransmitters
α-Synuclein
Iron is Essential for Life
• Red blood cell production, oxygen transport
• Neurotransmitter synthesis in neurons
• Energy production via ATP and activity of
many enzymes
Sources: Ritchie et al, 2012; DOI:10.4236/health.2012.431175; Cronin et al, 2019, doi.org/10.3389/fmolb.2019.00116
6
Increased Brain Iron in Parkinson’s Disease and
Multiple System Atrophy
Multiple System Atrophy
Parkinson’s disease
Substantia nigra (T)
n=7
n=9
Substantia nigra (pc)
n=8
n=3
Patients
*
Healthy
*
n = 13
Cerebellum
n = 24
0
10000
20000
30000
nmol iron/g of human brain
Control
n=8
n = 11
Caudate nucleus
n=8
n = 10
Putamen (M)
n=8
n = 10
Putamen (L)
n=8
n=8
Globus pallidus (M)
n=8
n=9
Globus pallidus (L)
n=8
n = 11
Substantia nigra (T)
n=6
n=9
Cerebellum
n=8
n = 12
Dexter et al. Brain.1991
Advanced Quantitative MRI to measure brain iron
MSA
Cerebral cortex
0
*
*
*
*
10000
20000
30000
nmol iron/g of human brain
Courtesy of P. Trujillo, D. Claassen
7
Treatment Approach: Address Underlying Pathology
Redistribute excess
labile iron
in the CNS
Reduce α‐synuclein
aggregation
and
Oxidative injury
Rescue brain cells/
neuronal function
Potential Disease Modifying Therapy for MSA
8
ATH434: Potential Disease Modifying Therapy
ATH434 binding to iron
• Small molecule drug candidate
• Decreases pathologic protein aggregation (α-synuclein) in CNS
• Iron chaperone: redistributes excess labile iron in CNS
• Oral medication
• Preferred over infusions and injections
• Potential to treat iron-related neurodegenerative disease
• Orphan Drug Designation in the US and EU for MSA treatment
• Development pathway endorsed by FDA and EMA
9
Multiple System Atrophy (MSA): Rare, Highly Debilitating and
Rapidly Progressive Neurodegenerative Disease
• Parkinsonian disorder with no approved
treatment
• Orphan disease: up to 50,000 patients in U.S.
• Disease characteristics
• Motor: Parkinsonism, uncoordinated movements,
balance problems and falls
• Autonomic dysfunction: blood pressure maintenance,
bladder control, bowel function
• Brain atrophy and α-synuclein accumulation in multiple
regions
• Over 50% require wheelchair in 5 years
• Median survival 7.5 years after symptom onset
Death can occur
Clinically Established MSA
Premotor MSA
Clinically Probable MSA
0
3
Years
6
Sources: Fanciulli, Wenning. NEJM 2015 | Wenning, et al. Mov Disorders 2022 | Coon, et al. Brain 2015 | Claassen,et al. Mov Disorders 2021 | Multiple System Atrophy: National Institute of Neurological
Disorders and Stroke (nih.gov)
9
10
Ongoing Treatment Studies with ATH434
Study
ATH434-201 – Phase 2
ATH434-202 – Phase 2
Design
Randomized, double-blind
Single arm, open-label
Objectives
Efficacy and safety of ATH434
Efficacy and safety of ATH434
Population
Early-stage MSA
Advanced MSA
Sample Size
N = 77
N = 10
Treatment
12 months
12 months
Brain MRI Biomarkers
Iron, volume
Iron, volume, glial pathology
Fluid Biomarkers
NfL^, Aggregated α-synuclein
NfL^, Aggregated α-synuclein
Other Biomarkers
Wearable movement sensors
─
Clinical Measures
Motor exam, autonomic function,
activities of daily living, global
measures
Motor exam, autonomic function,
activities of daily living, global
measures
^NfL: Neurofilament light chain
11
ATH434-202 Interim Clinical Data Confirms
Development Approach
Population: 10 with advanced MSA
Treatment: ATH434 75 mg bid
Assessment: 6 months
Safety: ATH434 well-tolerated and had no serious
adverse events related to study drug
UMSARS: Unified MSA Rating Scale (Part I)
Activities of Daily Living Scale
• Group change (n=10)^ compares favorably to
patients with similar disease severity*
Areas Assessed
• Speech
• Swallowing
• Handwriting
• Cutting food
• Dressing
• Hygiene
• Walking
• Falling
• Orthostatic symptoms
• Urinary Function
• Sexual Function
• Bowel Function
Global Impression of Change
• Overall rating from patient or clinician perspective
Clinical Responders
• 30% of participants showed stable or improved
neurological symptoms, based on UMSARS I and
Global Impression of change scores
^ Claassen. Mov. Disord. 2024.
* Wenning. Lancet Neurol 2013;12: 264–74.
12
ATH434-202 Interim Biomarker Data Support
Clinical Observations
Brain Volume
Neuronal Injury Marker
% change in CSF NfL at 6mon
Brain Iron
Iron content was stable in
the s. nigra, putamen and
globus pallidus over 12 mo
in clinical responders
Brain volume stable
between 6 and 12 mo in
clinical responders
80
60
40
20
0
-20
-40
ATH434-202
bioMuse
Mean levels of NfL, a marker of
neuronal injury only 2.7% in
ATH434-patients compared to
17.9% in untreated patients
(bioMUSE)
Participants who stabilized or improved had less advanced disease
MRI data at 6 months (n=10) and 12 months (n=3)
NfL (neurofilament light chain) data at 6 months.
13
Target Measures for Success
Favorable Safety Profile /
No Drug Related Serious Adverse Events
MSA
Phase 2
ATH434-201
Evidence of Drug Effect on Biomarker Endpoint or
Evidence of Benefit on Clinical Endpoint Relevant to MSA
Safety and Efficacy Data Support Advancing to Phase 3
14
Key Milestones
ATH434-201
Phase 2 Trial
Topline Data
ATH434-202
Preliminary
6 mo Data
BioMUSE
Data
ATH434-201
Phase 2 Trial
Study Complete
ATH434
MoA data
Scientific Meeting
Presentations
Jan 24
Feb 24
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
15
Alterity: Poised for Progress
• Targeting Orphan disease with no approved
treatments
• Natural History Study de-risked Phase 2
• Positive interim data in open label study
confirms clinical development approach
• Phase 2 double-blind data expected in January
2025
• Development team with multiple FDA approvals
• Cash balance of AU$9.28M as of 30 Sept 2024
Catalysts
MSA Natural History Study
H1 2024: Present new biomarker
data
ATH434-201 Phase 2 Double-Blind Trial
Nov 2023: Enrollment Complete
• Nov 2024: Study Complete
• Jan 2025: Topline Data
ATH434-202 Phase 2 Open label Trial
Jul 2024: Preliminary 6-mo Data
• H1 2025: 12-month Data
16
ASX:ATH | NASDAQ:ATHE
Share your feedback
Discover